Cogent Biosciences
Waltham
About Cogent Biosciences
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its antibody-coupled T-cell receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1M – $10M
- Total funding: $1.6B
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2025)
- Ticker: nasdaq:UMRX
- Website: cogentbio.com
- Phone: +1 617 843 5032
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cogent-biosciences-17747 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.